全球特发性肺纤维化（IPF）治疗药物市场（2023-2030）：类型（吡非尼酮、尼达尼布）、配销通路（医院药房、零售药房、线上提供者）、规模、份额、成长分析、预测

全球特发性肺纤维化（IPF）治疗市场规模预计将从2021年的33.1亿美元成长到2022年的35.4亿美元，预测期内年复合成长率为6.8%，到2030年预计将成长到美国2019 年为59.9 亿美元。

近年来，全球IPF药物市场经历了显着的成长和进步。特发性肺纤维化是一种慢性进行性肺部疾病，其特征是肺组织疤痕和增厚，导致呼吸困难和肺功能下降。该市场受到 IPF 盛行率增加、老年人口增加以及对该疾病认识不断提高等因素的推动。此外，高解析度电脑断层扫描 (HRCT) 等诊断技术的进步和新型治疗方法的开发也有助于市场成长。 IPF 的治疗方案包括吡非尼酮和尼达尼布等药物干预措施，这些干预措施已获得法规机构核准，可减缓疾病进展。此外，对于合格的末期 IPF 患者，肺移植被认为是可行的治疗选择。近年来，研发活动增加，导致潜在治疗标靶和有前途的候选药物的出现。此外，市场开始看到製药公司和研究机构之间的合作和伙伴关係，以加速有效治疗方案的发展。

然而，挑战仍然存在，例如治疗费用高、新兴地区患者意识低、缺乏明确的治疗方法等。

本报告调查了全球特发性肺纤维化（IPF）治疗药物市场，并提供了市场概况、市场各种影响因素分析、技术和创新趋势、法律制度以及市场规模趋势和预测。按不同分类和地区划分，竞争形势、主要企业概况等

目录

• 执行摘要
• 调查方法
• 母市场分析
  • 市场概况
  • 市场规模
  • 市场动态
    • 促进因素
    • 机会
    • 抑制因素
    • 任务
• 关键市场洞察
  • 技术分析
  • 价格分析
  • 供应链分析
  • 价值链分析
  • 市场生态系统
  • 智慧财产权分析
  • 贸易分析
  • 启动分析
  • 原料分析
  • 创新矩阵
  • 研发线产品分析
  • 总体经济指标
  • 重点投资分析
  • 关键成功因素
  • 竞争程度
  • 市场动态及展望
    • 市场动态
      • 促进因素
      • 机会
      • 抑制因素
      • 任务
  • 法规状况
  • 波特的分析
  • Skyquest 对未来颠覆的独家见解
• 按类型分類的全球特发性肺纤维化 (IPF) 治疗市场
  • 市场概况
  • 吡非尼酮
  • 尼达尼布
• 按配销通路的全球特发性肺纤维化（IPF）治疗市场
  • 市场概况
  • 医院药房
  • 零售药房/线上提供者
• 按地区分類的全球特发性肺纤维化（IPF）治疗市场
  • 市场概况
  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东/非洲
• 竞争形势
  • 前5名企业对比
  • 主要企业市场地位
  • 主要企业的招募策略
  • 关键成功策略
  • 近期市集活动
  • 主要企业市场占有率
• 主要企业简介
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Boehringer Ingelheim
  • GNI Group Ltd
  • F. Hoffmann-La Roche Ltd.
  • Shiongi co Ltd
  • Mission Therapeutics
  • Biogen, Inc.
  • Galapagos NV
  • FibroGen, Inc.
  • GlaxoSmithKline plc
  • Genzyme Corporation
  • Actelion Pharmaceuticals Ltd
  • Promedior, Inc.
  • MediciNova, Inc.
  • Cipla Limited
  • InterMune, Inc.
  • Phytopharm plc
  • Galecto Biotech AB
  • Celtaxsys, Inc.

Global Idiopathic Pulmonary Fibrosis Treatment Market size was valued at USD 3.31 Billion in 2021 and is poised to grow from USD 3.54 Billion in 2022 to USD 5.99 Billion by 2030, at a CAGR of 6.8% during the forecast period (2023-2030).

The Global Idiopathic Pulmonary Fibrosis (IPF) Treatment Market has witnessed significant growth and advancements in recent years. Idiopathic pulmonary fibrosis is a chronic and progressive lung disorder characterized by the scarring and thickening of lung tissues, leading to breathing difficulties and reduced lung function. The market for IPF treatment has been driven by factors such as increasing prevalence of IPF, growing geriatric population, and rising awareness about the disease. Furthermore, advancements in diagnostic techniques, such as high-resolution computed tomography (HRCT), and the development of novel therapies have also contributed to the market growth. The treatment landscape for IPF includes pharmacological interventions, such as pirfenidone and nintedanib, which are approved by regulatory authorities for slowing down disease progression. Additionally, lung transplantation is considered as a viable treatment option for eligible patients with end-stage IPF. In recent years, there has been a surge in research and development activities, leading to the emergence of potential therapeutic targets and promising drug candidates. Moreover, the market is witnessing collaborations and partnerships between pharmaceutical companies and research institutions to accelerate the development of effective treatment options. However, challenges such as high treatment costs, limited patient awareness in developing regions, and the lack of definitive curative therapies still persist. Nevertheless, the global IPF treatment market is expected to continue its growth trajectory, driven by ongoing research, technological advancements, and a growing focus on improving the quality of life for IPF patients.

Top-down and bottom-up approaches were used to estimate and validate the size of the global Emergency Lighting Systems Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined by using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Idiopathic Pulmonary Fibrosis Treatment Market Segmental Analysis

The Global Idiopathic Pulmonary Fibrosis Treatment Market is segmented on the basis of type, distribution channel, and region. Based on type, the market can be segmented into Pirfenidone and nintedanib. Based on distribution channel, the market is segmented into Hospital pharmacies, retail pharmacies and online providers. Based on region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Global Idiopathic Pulmonary Fibrosis Treatment Market Dynamics

Drivers of the Global Idiopathic Pulmonary Fibrosis Treatment Market

Increasing prevalence of IPF

One key driver of the Global Idiopathic Pulmonary Fibrosis (IPF) Treatment Market is the increasing prevalence of IPF. The rising incidence of IPF globally, particularly among the aging population, is driving the demand for effective treatment options. As the number of diagnosed IPF cases continues to grow, there is a greater need for pharmaceutical interventions and therapies that can slow down disease progression and improve patients' quality of life.

Restraints in the Global Idiopathic Pulmonary Fibrosis Treatment Market

High treatment costs

One key restraint of the IPF treatment market is the high treatment costs. The cost of IPF treatment, including medications, diagnostic tests, and supportive care, can be significant and pose a financial burden on patients and healthcare systems. The high cost of treatment may limit access to effective therapies, especially in regions with limited healthcare resources or inadequate insurance coverage. This can result in disparities in treatment availability and affordability, impacting patients' ability to access appropriate care and potentially leading to suboptimal outcomes.

Market Trends of Global Idiopathic Pulmonary Fibrosis Treatment Key

Increasing focus on personalized medicine and precision therapeutics

One key market trend in the Global Idiopathic Pulmonary Fibrosis (IPF) Treatment Market is the increasing focus on personalized medicine and precision therapeutics. With advancements in understanding the underlying mechanisms and heterogeneity of IPF, there is a growing emphasis on tailoring treatment approaches based on individual patient characteristics and disease subtypes. This trend involves the identification of biomarkers, genetic profiling, and the development of targeted therapies that can address specific molecular pathways associated with IPF progression. The aim is to improve treatment outcomes by providing more precise and effective therapies that have the potential to slow down disease progression and improve patients' quality of life.

Table of Contents

• Executive Summary
  • Market Overview
  • Wheel of Fortune
• Research Methodology
  • Information Procurement
  • Secondary & Primary Data Sources
  • Market Size Estimation
  • Market Assumptions & Limitations
• Parent Market Analysis
  • Market Overview
  • Market Size
  • Market Dynamics
• Drivers
• Opportunities
• Restraints
• Challenges
• Key Market Insights
  • Technology Analysis
  • Pricing Analysis
  • Supply Chain Analysis
  • Value Chain Analysis
  • Ecosystem of the Market
  • IP Analysis
  • Trade Analysis
  • Startup Analysis
  • Raw Material Analysis
  • Innovation Matrix
  • Pipeline Product Analysis
  • Macroeconomic Indicators
  • Top Investment Analysis
  • Key Success Factor
  • Degree of Competition
• Market Dynamics & Outlook
  • Market Dynamics
• Drivers
• Opportunities
• Restraints
• Challenges
  • Regulatory Landscape
  • Porters Analysis
• Competitive rivalry
• Threat of Substitute Products
• Bargaining Power of Buyers
• Threat of New Entrants
• Bargaining Power of Suppliers
  • Skyquest Special Insights on Future Disruptions
• Political Impact
• Economic Impact
• Social Impact
• Technical Impact
• Environmental Impact
• Legal Impact
• Global Idiopathic Pulmonary Fibrosis Treatment Market by Type
  • Market Overview
  • Pirfenidone and nintedanib
• Global Idiopathic Pulmonary Fibrosis Treatment Market by Distribution channel
  • Market Overview
  • Hospital pharmacies
  • retail pharmacies and online providers
• Global Idiopathic Pulmonary Fibrosis Treatment Market Size by Region
  • Market Overview
  • North America
• USA
• Canada
  • Europe
• Germany
• Spain
• France
• UK
• Rest of Europe
  • Asia Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
  • Latin America
• Brazil
• Rest of Latin America
  • Middle East & Africa (MEA)
• GCC Countries
• South Africa
• Rest of MEA
• Competitive Landscape
  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2021
  • Strategies Adopted by Key Market Players
  • Top Winning Strategies
• By Development
• By Company
• By Year
  • Recent Activities in the Market
  • Key Companies Market Share (%), 2021
• Key Company Profiles
  • AstraZeneca PLC (UK)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Bristol-Myers Squibb Company (US)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Boehringer Ingelheim (Germany)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • GNI Group Ltd (Japan)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • F. Hoffmann-La Roche Ltd. (Switzerland)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Shiongi co Ltd (Japan)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Mission Therapeutics (UK)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Biogen, Inc. (US)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Galapagos NV (Belgium)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • FibroGen, Inc. (US)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • GlaxoSmithKline plc (UK)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Genzyme Corporation (US)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Actelion Pharmaceuticals Ltd (Switzerland)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Promedior, Inc. (US)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • MediciNova, Inc. (US)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Cipla Limited (India)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • InterMune, Inc. (US)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Phytopharm plc (UK)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Galecto Biotech AB (Sweden)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Celtaxsys, Inc. (US)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments